Inovio Pharmaceuticals Announces New Public Equity Offering

Inovio Pharmaceuticals ( (INO) ) has issued an announcement.

On April 2, 2026, Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler & Co. for a public offering of 12,500,000 shares of common stock and accompanying Series A and Series B warrants, or pre-funded warrants in lieu thereof, at a combined public offering price of $1.40 per share and warrants. The company also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares and related warrants, with closing of the offering expected on or about April 6, 2026, subject to customary conditions.

The transaction is expected to yield approximately $16 million in net proceeds for Inovio, assuming no exercise of the underwriters’ option or the warrants. The structure of the deal, including short- and long-dated warrants and ownership caps, provides investors with leveraged exposure while limiting immediate concentration, and the new capital should support Inovio’s DNA medicine programs and bolster its financial position in a challenging biotech funding environment.

The most recent analyst rating on (INO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.

Spark’s Take on INO Stock

According to Spark, TipRanks’ AI Analyst, INO is a Neutral.

The score is primarily held down by very weak financial performance (minimal revenue, large losses, and sustained cash burn). Offsetting this somewhat are constructive earnings-call developments around INO-3107 and disciplined cost reductions, while technicals suggest only modest near-term stabilization within a weaker longer-term trend and valuation remains constrained by ongoing losses.

To see Spark’s full report on INO stock, click here.

More about Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing DNA medicines aimed at treating and protecting people from HPV-related diseases, cancer and infectious diseases. The company’s technology is designed to optimize the design and delivery of DNA medicines that stimulate the body to produce its own disease-fighting tools.

Inovio operates in the biotech sector with a portfolio centered on innovative DNA-based therapeutics, positioning it within the competitive market for next-generation immunotherapies targeting viral infections and oncology indications.

Average Trading Volume: 1,289,658

Technical Sentiment Signal: Sell

Current Market Cap: $78.07M

Learn more about INO stock on TipRanks’ Stock Analysis page.